Tiny transcriptome biotech secures Series A to ramp up automated R&D efforts in race toward clinic
A Colorado company is looking to re-up its efforts to expand and go into the clinic, and thanks to some fresh cash from an investing group, the biotech is headed in that direction.
Arpeggio Biosciences announced Wednesday morning that it successfully raised $17 million in a Series A round, two years after a $3.2 million seed round and four years after being initially founded. CEO and co-founder Joey Azofeifa tells Endpoints News that the funding will initially go to pipeline development and automating its compound-screening efforts.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.